COMMUNIQUÉS West-GlobeNewswire

Ossur Hf : Transactions in relation to share buyback program
27/12/2017
Announcement from Össur hf. No. 89/2017 Reykjavík, 27 December 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
HempAmericana Provides Detailed View Toward an Exciting 2018
27/12/2017
NEW YORK, Dec. 27, 2017 (GLOBE NEWSWIRE) -- HempAmericana, Inc. (OTC:HMPQ) (the “Company”) is proud to provide a year-end shareholder update on the Company’s progress toward its key strategic objectives as 2017 winds [...]
Sharecare to Present at J.P. Morgan Healthcare Conference for Fifth Consecutive Year
27/12/2017
ATLANTA, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Sharecare , the digital health company that helps people manage all their health in one place, today announced it will present at the 36th annual J.P. Morgan Healthcare [...]
Beaucoup de donneurs de sang répondent à l’appel, mais il en faut plus
27/12/2017
OTTAWA, 27 déc. 2017 (GLOBE NEWSWIRE) -- La Société canadienne du sang a observé une augmentation importante des dons de sang depuis le 18 décembre, date à laquelle elle a lancé un appel aux donneurs pour combler les 35 [...]
TOMI Environmental Solutions, Inc. Starts New Year With Inclusion in EPA Lists G, L, and M
27/12/2017
BEVERLY HILLS, Calif., Dec. 27, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, [...]
American Health Council Names Carl Roland, PharmD, MS to Industry Board
27/12/2017
NEW YORK, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Carl Roland, Senior Director at Pfizer, has been selected to join the Industry Board at the American Health Council. He will be sharing his knowledge and expertise in Clinical [...]
Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
27/12/2017
Actinium expects enhanced awareness of Iomab-B at ASH annual meeting and expanded site activity to enable completion of trial enrollment by end of 2018, in-line with prior forecast NEW YORK, Dec. 27, 2017 (GLOBE [...]
UPDATE -- Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
27/12/2017
Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution WALTHAM, Mass., Dec. 27, 2017 ( [...]
Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
27/12/2017
Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution WALTHAM, Mass., Dec. 27, 2017 ( [...]
Agritek Holdings, Inc. Announces $1,000,000 Capital Infusion With Institutional Investor And Eliminates First $200,000 Of Existing Toxic Convertible Debt With Final $500,000 In Convertible Debt To Be Paid By Year End.
27/12/2017
LOS ANGELES, CA, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Agritek Holdings, Inc. (OTCQB: AGTK) www.AgritekHoldings.com , a fully integrated, active real estate investor for the cannabis sector and consultant for multiple [...]
Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases
27/12/2017
CAMBRIDGE, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to [...]
Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel
27/12/2017
BUFFALO, N.Y., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme
27/12/2017
CHARLOTTESVILLE, Va., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN ) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of [...]
Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
27/12/2017
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data [...]
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
27/12/2017
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced [...]
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
27/12/2017
CARMIEL, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
ProQR Announces Extraordinary General Meeting of Shareholders
27/12/2017
LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq: PRQR ), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018, at 16: [...]
Blood donors step up, but more still needed
27/12/2017
OTTAWA, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Canadian Blood Services has seen a notable increase in donations since Dec. 18 when it issued an urgent call for eligible donors to fill 35,000 open appointments by Jan. 6. [...]
VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.
27/12/2017
TEL AVIV, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced the study initiation and first patient in its Phase 3 pivotal registration trial, OVAL, studying its lead candidate VB [...]

Pages